Assisted Reproductive Technology (ART) Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,850	150 Pages	Fortune Business Insights Pvt. Ltd.	May, 2025	FOB20106904

Best Price Guarantee
Price	from $4,850
Length	150 Pages
Publisher	Fortune Business Insights Pvt. Ltd.
Published Date	May, 2025
SKU	FOB20106904

Table of Contents
Description

Growth Factors of Assisted Reproductive Technology (ART) Marke

The global Assisted Reproductive Technology (ART) market has witnessed significant growth in recent years and is poised to continue its upward trajectory. Valued at approximately USD 21.32 billion in 2018, the market is projected to reach USD 45.06 billion by 2026, reflecting a compound annual growth rate (CAGR) of 9.8% during the forecast period from 2019 to 2026 .

Market Drivers

Several factors contribute to the expansion of the ART market:

1. Rising Infertility Rates: Increasing infertility rates, attributed to factors such as delayed marriages, lifestyle changes, and environmental influences, are driving the demand for ART services.

2. Technological Advancements: Innovations in ART techniques, including In-Vitro Fertilization (IVF), Artificial Insemination-Intrauterine Insemination (AI-IUI), and Frozen Embryo Transfer (FET), have improved success rates and broadened treatment options.

3. Government Initiatives: Supportive policies and regulations, such as the establishment of ART and surrogacy boards in regions like Odisha, India, are enhancing the accessibility and ethical standards of fertility treatments .

Market Segmentation

The ART market can be segmented based on technique, procedure, and end-user:

By Technique:

In-Vitro Fertilization (IVF): Dominates the market due to its high success rates and widespread adoption.

Artificial Insemination-Intrauterine Insemination (AI-IUI): A less invasive option with increasing popularity.

Frozen Embryo Transfer (FET): Gaining traction for its convenience and flexibility.

By Procedure:

Fresh Donor: Involves the use of fresh eggs or sperm from a donor.

Fresh Non-donor: Utilizes the patient's own eggs or sperm.

Frozen Donor: Employs frozen eggs or sperm from a donor.

Frozen Non-donor: Uses the patient's own frozen eggs or sperm.

By End-User:

Fertility Clinics: The primary setting for ART procedures.

Hospitals: Offer ART services, particularly in specialized departments.

Regional Insights

Europe: Led the global ART market in 2018, generating USD 8.78 billion in revenue, driven by a high prevalence of infertility and increasing demand for fertility services .

North America: The United States is witnessing significant growth in the ART market, fueled by increasing infertility rates, advancements in medical technologies, and rising awareness about reproductive treatments.

Asia-Pacific: Expected to register the highest growth rate during the forecast period, primarily due to rising awareness about infertility treatments, improving healthcare infrastructure, and increasing disposable incomes .

Challenges

Despite the positive growth trajectory, the ART market faces several challenges:

1. High Treatment Costs: The expense associated with ART procedures can be prohibitive, limiting access for many individuals.

2. Success Rates: Variable success rates across different age groups and treatment types can impact patient outcomes and satisfaction.

3. Socio-Ethical Concerns: Ethical considerations surrounding ART, such as embryo selection and surrogacy, can influence public perception and acceptance.

Future Outlook

The ART market is expected to continue its growth, driven by ongoing advancements in technology, increasing awareness, and supportive government policies. However, addressing challenges related to cost, success rates, and ethical concerns will be crucial for sustaining this growth and ensuring equitable access to ART services.

ATTRIBUTE DETAILS

Study Period 2015-2026

Base Year 2018

Forecast Period 2019-2026

Historical Period 2015-2017

Unit Value (USD billion)

Segmentation By Technique

In Vitro Fertilization (IVF)

Artificaial Insemination (AI-IUI)

Frozen Embryo Transfer (FET)

Others

By Procedure

Fresh Donor

Fresh Non-donor

Frozen Donor

Frozen Non-donor

By End User

Hospitals

Fertility Clinics

By Geography

North America (U.S. and Canada)

Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)

Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)

Latin America (Brazil, Mexico, and Rest of Latin America)

Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)

Please Note:

It will take 5-6 business days to complete the report upon order confirmation.

1. Introduction: 1.1. Research Scope; 1.2. Market Segmentation; 1.3. Research Methodology; 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics: 3.1. Market Drivers; 3.2. Market Restraints; 3.3. Market Opportunities
4. Key Insights: 4.1. Prevalence of Infertility, By Key Regions/Countries, 2018; 4.2. Number of Registered Fertility Clinics for Key Countries; 4.3. Technological Advancements in ART procedures; 4.4. Key Industry Developments – Partnerships, Mergers and Acquisitions
5. Global Assisted Reproductive Technologies (ART) Market Analysis, Insights and Forecast, 2015-2026: 5.1. Key Findings / Summary; 5.2. Market Analysis, Insights and Forecast – By Technique; 5.2.1. In Vitro Fertilization (IVF); 5.2.2. Artificial Insemination (AI-IUI); 5.2.3. Frozen Embryo Transfer (FET); 5.2.4. Others; 5.3. Market Analysis, Insights and Forecast – By Procedure; 5.3.1. Fresh Donor; 5.3.2. Fresh Non-donor; 5.3.3. Frozen Donor; 5.3.4. Frozen Non-donor; 5.4. Market Analysis, Insights and Forecast – By End User; 5.4.1. Hospitals; 5.4.2. Fertility Clinics; 5.5. Market Analysis, Insights and Forecast – By Region; 5.5.1. North America; 5.5.2. Europe; 5.5.3. Asia Pacific; 5.5.4. Latin America; 5.5.5. Middle East & Africa
6. North America Assisted Reproductive Technologies (ART) Market Analysis, Insights and Forecast, 2015-2026: 6.1. Key Findings / Summary; 6.2. Market Analysis, Insights and Forecast – By Technique; 6.2.1. In Vitro Fertilization (IVF); 6.2.2. Artificial Insemination (AI-IUI); 6.2.3. Frozen Embryo Transfer (FET); 6.2.4. Others; 6.3. Market Analysis, Insights and Forecast – By Procedure; 6.3.1. Fresh Donor; 6.3.2. Fresh Non-donor; 6.3.3. Frozen Donor; 6.3.4. Frozen Non-donor; 6.4. Market Analysis, Insights and Forecast – By End User; 6.4.1. Hospitals; 6.4.2. Fertility Clinics; 6.5. Market Analysis, Insights and Forecast – By Country/Sub-region; 6.5.1. U.S.; 6.5.2. Canada
7. Europe Assisted Reproductive Technologies (ART) Market Analysis, Insights and Forecast, 2015-2026: 7.1. Key Findings / Summary; 7.2. Market Analysis, Insights and Forecast – By Technique; 7.2.1. In Vitro Fertilization (IVF); 7.2.2. Artificial Insemination (AI-IUI); 7.2.3. Frozen Embryo Transfer (FET); 7.2.4. Others; 7.3. Market Analysis, Insights and Forecast – By Procedure; 7.3.1. Fresh Donor; 7.3.2. Fresh Non-donor; 7.3.3. Frozen Donor; 7.3.4. Frozen Non-donor; 7.4. Market Analysis, Insights and Forecast – By End User; 7.4.1. Hospitals; 7.4.2. Fertility Clinics; 7.5. Market Analysis, Insights and Forecast – By Country/Sub-region; 7.5.1. U.K.; 7.5.2. Germany; 7.5.3. France; 7.5.4. Spain; 7.5.5. Italy; 7.5.6. Scandinavia; 7.5.7. Rest of Europe
8. Asia Pacific Assisted Reproductive Technologies (ART) Market Analysis, Insights and Forecast, 2015-2026: 8.1. Key Findings / Summary; 8.2. Market Analysis, Insights and Forecast – By Technique; 8.2.1. In Vitro Fertilization (IVF); 8.2.2. Artificial Insemination (AI-IUI); 8.2.3. Frozen Embryo Transfer (FET); 8.2.4. Others; 8.3. Market Analysis, Insights and Forecast – By Procedure; 8.3.1. Fresh Donor; 8.3.2. Fresh Non-donor; 8.3.3. Frozen Donor; 8.3.4. Frozen Non-donor; 8.4. Market Analysis, Insights and Forecast – By End User; 8.4.1. Hospitals; 8.4.2. Fertility Clinics; 8.5. Market Analysis, Insights and Forecast – By Country/Sub-region; 8.5.1. Japan; 8.5.2. China; 8.5.3. India; 8.5.4. Australia; 8.5.5. Southeast Asia; 8.5.6. Rest of Asia Pacific
9. Latin America Assisted Reproductive Technologies (ART) Market Analysis, Insights and Forecast, 2015-2026: 9.1. Key Findings / Summary; 9.2. Market Analysis, Insights and Forecast – By Technique; 9.2.1. In Vitro Fertilization (IVF); 9.2.2. Artificial Insemination (AI-IUI); 9.2.3. Frozen Embryo Transfer (FET); 9.2.4. Others; 9.3. Market Analysis, Insights and Forecast – By Procedure; 9.3.1. Fresh Donor; 9.3.2. Fresh Non-donor; 9.3.3. Frozen Donor; 9.3.4. Frozen Non-donor; 9.4. Market Analysis, Insights and Forecast – By End User; 9.4.1. Hospitals; 9.4.2. Fertility Clinics; 9.5. Market Analysis, Insights and Forecast – By Country/Sub-region; 9.5.1. Brazil; 9.5.2. Mexico; 9.5.3. Rest of Latin America
10. Middle East & Africa Assisted Reproductive Technologies (ART) Market Analysis, Insights and Forecast, 2015-2026: 10.1. Key Findings / Summary; 10.2. Market Analysis, Insights and Forecast – By Technique; 10.2.1. In Vitro Fertilization (IVF); 10.2.2. Artificial Insemination (AI-IUI); 10.2.3. Frozen Embryo Transfer (FET); 10.2.4. Others; 10.3. Market Analysis, Insights and Forecast – By Procedure; 10.3.1. Fresh Donor; 10.3.2. Fresh Non-donor; 10.3.3. Frozen Donor; 10.3.4. Frozen Non-donor; 10.4. Market Analysis, Insights and Forecast – By End User; 10.4.1. Hospitals; 10.4.2. Fertility Clinics; 10.5. Market Analysis, Insights and Forecast – By Country/Sub-region; 10.5.1. GCC Countries; 10.5.2. South Africa; 10.5.3. Rest of Middle East & Africa
11. Competitive Analysis: 11.1. Key Industry Developments; 11.2. Company Profiles (Overview, Products & Services, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability)); 11.2.1. Bloom IVF Centre; 11.2.1.1. Overview,; 11.2.1.2. Products & Services,; 11.2.1.3. SWOT Analysis,; 11.2.1.4. Recent Developments,; 11.2.1.5. Strategies,; 11.2.1.6. Financials (Based on Availability); 11.2.2. California Cryobank; 11.2.2.1. Overview,; 11.2.2.2. Products & Services,; 11.2.2.3. SWOT Analysis,; 11.2.2.4. Recent Developments,; 11.2.2.5. Strategies,; 11.2.2.6. Financials (Based on Availability); 11.2.3. CARE Fertility; 11.2.3.1. Overview,; 11.2.3.2. Products & Services,; 11.2.3.3. SWOT Analysis,; 11.2.3.4. Recent Developments,; 11.2.3.5. Strategies,; 11.2.3.6. Financials (Based on Availability); 11.2.4. Monash IVF Group; 11.2.4.1. Overview,; 11.2.4.2. Products & Services,; 11.2.4.3. SWOT Analysis,; 11.2.4.4. Recent Developments,; 11.2.4.5. Strategies,; 11.2.4.6. Financials (Based on Availability); 11.2.5. Carolinas Fertility Institute; 11.2.5.1. Overview,; 11.2.5.2. Products & Services,; 11.2.5.3. SWOT Analysis,; 11.2.5.4. Recent Developments,; 11.2.5.5. Strategies,; 11.2.5.6. Financials (Based on Availability); 11.2.6. European Sperm Bank; 11.2.6.1. Overview,; 11.2.6.2. Products & Services,; 11.2.6.3. SWOT Analysis,; 11.2.6.4. Recent Developments,; 11.2.6.5. Strategies,; 11.2.6.6. Financials (Based on Availability); 11.2.7. INVO Bioscience; 11.2.7.1. Overview,; 11.2.7.2. Products & Services,; 11.2.7.3. SWOT Analysis,; 11.2.7.4. Recent Developments,; 11.2.7.5. Strategies,; 11.2.7.6. Financials (Based on Availability); 11.2.8. Apollo Hospitals Enterprise Ltd.; 11.2.8.1. Overview,; 11.2.8.2. Products & Services,; 11.2.8.3. SWOT Analysis,; 11.2.8.4. Recent Developments,; 11.2.8.5. Strategies,; 11.2.8.6. Financials (Based on Availability); 11.2.9. Other Players; 11.2.9.1. Overview,; 11.2.9.2. Products & Services,; 11.2.9.3. SWOT Analysis,; 11.2.9.4. Recent Developments,; 11.2.9.5. Strategies,; 11.2.9.6. Financials (Based on Availability)